Greece-based pharmaceutical manufacturer Demo on Tuesday announced an ambitious investment plan of 356 million euros up until 2027, mainly aiming at a further expansion into the production of raw materials, production of final products, as R&D and biotechnology.
According to CEO Dimitris Demos, the capital investment plan envisions an expansion of the main Demo plant due north of Athens, at the Kryoneri site; three new raw materials units and four pharmaceutical production units in Tripoli, Arcadia prefecture, southern Greece; a new R&D lab in the northern city of Thessaloniki and high-profile new unit for the production of monoclonal antibodies along with a “BioAcademy” in the greater Athens area.
